Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of X-Linked Hypophosphatemia in Children

February 23, 2018

Responsive image

TOKYO, LONDON and NOVATO, California, February 23, 2018 /PRNewswire/ —
Crysvita is the First Treatment for XLH that Targets the Underlying Cause of the Disease
Crysvita Acknowledged by European Medicines Agency as an Outstanding Contribution to PublicHealth
Kyowa Hakko…

Category: Precious Metals